ClinicalTrials.gg
RecruitingNCT07203755Updated Dec 31, 2025

Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine

A Phase 1 interventional study of Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4) and DTcP-Hib-MCV4 in Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis and Haemophilus Influenzae Type B Infection, sponsored by CanSino Biologics Inc.. Recruiting at 1 site in China. Open to participants aged 2 Months to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by CanSino Biologics Inc. · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
2 Months to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Diphtheria with a site in China — 7 open to participants now, 10 under way, 4 of them phase 3. Diphtheria · China.

Planned enrollment
22nd of 27
260 · median 660
Started
2025
with 2 others
Phase 1
5 of 27
2 open now
Registered
24th of 27
by date
Lead sponsor
6 of 27
CanSino Biologics Inc.

Among the 27 studies in Diphtheria with a site in China, this one is the 22nd largest by planned enrollment, is one of 3 that started in 2025, is one of 5 in phase 1, and was the 24th registered.

Diphtheria

267 studies on the registry are indexed under Diphtheria; 17 are open to participants now.

Browse Diphtheria studies →

Open to participants now

7 of the 27 studies in Diphtheria with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 2 Months to 6 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Diphtheria with a site in China, or all of them as a file.
02

Study summary

This clinical trial is conducted in two parts. Part One employs a randomized, partially blinded, dose-escalation, partially active-controlled design. Part Two utilizes a randomized, blinded, placebo-controlled design. Part One is divided into four stages based on age and vaccine dose levels. Part Two consists of the 2-month-old vaccine/placebo groups.

03

Conditions studied

  • Diphtheria, Tetanus and Acellular Pertussis
  • Epidemic Meningitis
  • Haemophilus Influenzae Type B Infection

Keywords

  • Combined Vaccine
  • Safety
  • Immunogenicity
  • Ages 2 months to 6 years
04

Who can participate

Ages eligible
2 Months to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General Inclusion Criteria:

  • Participants aged 2 months (60-89 days), 3 months (90-119 days), 18-24 months, and 6 years of age, with legal guardians or authorized representatives willing to provide identification documentation;
  • Legal guardians or authorized representatives provide , voluntarily sign the informed consent form, and are able to comply with the requirements of the clinical trial protocol;

Part I: Specific Inclusion Criteria:

  • Individuals aged 18-24 months who have completed a 3-dose DTaP-containing vaccine series and a meningococcal-containing vaccine primary series, but have not received a DTaP-containing booster dose;
  • Individuals aged 6 years who have completed 4 doses of DTaP-containing vaccine but have not received the 5th DTaP-containing vaccine dose; and have only completed the first meningococcal-containing vaccine booster dose, without receiving the second meningococcal-containing vaccine booster dose at age 6.

Exclusion criteria

Exclusion Criteria:

General Exclusion Criteria for First Dose:

  • Infants born prematurely (delivery before 37 weeks gestation) or with low birth weight (\<2500g) at 2 months (60-89 days) or 3 months (90-119 days) of age;
  • Infants aged 2 months (60-89 days) or 3 months (90-119 days) with history of abnormal labor, asphyxia requiring resuscitation, or neurological impairment;
  • Severe congenital malformations or developmental disorders, genetic defects, or severe malnutrition;
  • History of severe adverse reactions or anaphylaxis to vaccines or vaccine components, such as urticaria, dyspnea, angioedema;
  • History of epilepsy, convulsions, seizures, cerebral palsy, psychiatric disorders, or family history thereof; or history of progressive neurological diseases (e.g., Guillain-Barré syndrome, brachial plexus neuritis);
  • Diagnosed with congenital or acquired immunodeficiency, infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), juvenile rheumatoid arthritis (JRA), or other diseases;
  • Acute illness (e.g., fever ≥38.5°C, diarrhea) or acute exacerbation of chronic disease within 3 days prior to receiving the product;
  • Known or suspected severe chronic diseases (including: severe respiratory disease, severe cardiovascular disease, liver/kidney disease, severe dermatology conditions, , etc.);
  • Current anal abscess or severe eczema;
  • Clinically diagnosed coagulation disorders (e.g., factor deficiency, bleeding disorders, abnormalities) or significant bruising/coagulation impairment;
  • Asplenia, functional asplenia, or splenectomy due to any cause;
  • Continuous treatment with , immunomodulators, or cytotoxic agents (exceeding 10 days) within the past 6 months; inhaled or topical are permitted;
  • Receipt of blood products or immunoglobulins (excluding immunoglobulin) within the past 3 months;
  • Received an injectable within 14 days, or any other vaccine within 7 days;
  • Taken antipyretic analgesics or antiallergic medications within 3 days;
  • Fever present prior to vaccination, with axillary temperature ≥37.3°C (99.3°F);
  • Plans to participate in or is currently participating in any other drug/vaccine clinical trial;
  • Any other factors deemed by the investigator to make the subject unsuitable for participation in the clinical trial.

Part I: Exclusion Criteria for the First Dose:

  • Infants aged 2 months (60-89 days) who have received vaccines containing meningococcal, DTP, or Haemophilus influenzae type b components;
  • Infants aged 3 months (90-119 days) who have received a vaccine containing meningococcal components;
  • Individuals aged 18-24 months who have received vaccines containing meningococcal or Haemophilus influenzae type b components within the past six months;
  • Individuals aged 18-24 months with abnormal pre-vaccination blood count or urinalysis results deemed by the investigator;
  • Children aged 6 years who, prior to vaccination, exhibit abnormal results in relevant indicators of complete blood count, blood biochemistry, coagulation function, or urinalysis, and are deemed clinically significant by the investigator;
  • Individuals with a history of any of the following diseases: meningococcal meningitis, Haemophilus influenzae type b disease, pertussis, diphtheria, or tetanus.

Part II: Specific Exclusion Criteria for the First Dose

  • History of vaccination with any meningococcal-containing vaccine;
  • History of meningococcal disease. General Exclusion Criteria for Subsequent Doses:
  • Occurrence of a serious adverse event related to vaccination following the previous dose;
  • Vaccine-related Grade 3 or higher allergic reaction following the previous dose;
  • Any other factors deemed by the investigator to make the subject unsuitable for continued participation in the clinical trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Part I, 1A, low dose, 6 year-old

    One dose of DTcP-Hib-MCV4 on Day 0

    Biological: Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4)

  • Experimental
    Part I, 2A, low dose, 18~24 month-old

    One dose of DTcP-Hib-MCV4 on Day 0

    Biological: DTcP-Hib-MCV4

  • Experimental
    Part I, 2B, high dose, 18~24 month-old

    One dose of DTcP-Hib-MCV4 on Day 0

    Biological: DTcP-Hib-MCV4

  • Experimental
    Part I, 3A, low dose, 2 month-old

    3 doses of DTcP-Hib-MCV4 at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

    Biological: DTcP-Hib-MCV4

  • Experimental
    Part I, 3B, high dose, 2 month-old

    3 doses of DTcP-Hib-MCV4 at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

    Biological: DTcP-Hib-MCV4

  • Active comparator
    Part I, 3C, 2 month-old

    3 doses of DTcP at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

    Biological: Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP)

  • Active comparator
    Part I, 3D, 2 month-old

    3 doses of Hib at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

    Biological: Haemophilus influenzae type b (Conjugate) (Hib)

  • Active comparator
    Part I, 3E, 2 month-old

    3 doses of MCV4 at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

    Biological: Meningococcal Group ACYW135 (Conjugate) (MCV4)

  • Active comparator
    Part I, 4A, 3 month-old

    3 doses of MCV4 at 0, 1, and 2 months, followed by a booster dose at 12 months of age.

    Biological: MCV4

  • Experimental
    Part II, Vaccine Group, 2 month-old

    3 doses of MCV4 at 0, 2, and 4 months.

    Biological: MCV4

  • Placebo comparator
    Part II, Placebo Group, 2 month-old

    3 doses of NS at 0, 2, and 4 months.

    Other: Sodium Chloride Injection (0.9%) (Saline Solution) (NS)

Interventions

  • BiologicalAdsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4)

    1 dose of DTcP-Hib-MCV4 vaccine (0.5ml) on day 0

  • BiologicalDTcP-Hib-MCV4

    1 dose of DTcP-Hib-MCV4 vaccine (0.5ml) on day 0

  • BiologicalDTcP-Hib-MCV4

    1 dose of DTcP-Hib-MCV4 vaccine (0.5ml) on day 0

  • BiologicalDTcP-Hib-MCV4

    3 doses of DTcP-Hib-MCV4 (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

  • BiologicalDTcP-Hib-MCV4

    3 doses of DTcP-Hib-MCV4 (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

  • BiologicalAdsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP)

    3 doses of DTcP (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

  • BiologicalHaemophilus influenzae type b (Conjugate) (Hib)

    3 doses of Hib (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

  • BiologicalMeningococcal Group ACYW135 (Conjugate) (MCV4)

    3 doses of MCV4 (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

  • BiologicalMCV4

    3 doses of MCV4 (0.5ml) at 0, 1, and 2 months, followed by a booster dose at 12 months of age.

  • BiologicalMCV4

    3 doses of MCV4 (0.5ml) at 0, 2, and 4 months.

  • OtherSodium Chloride Injection (0.9%) (Saline Solution) (NS)

    3 doses of NS (0.5ml) at 0, 2, and 4 months.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse reactions

    Time frame: Parts I and II: Within 14 days after each dose

Secondary outcomes

  1. Incidence of adverse events

    Time frame: Part I Sections 1A, 2A, 2B: Within 14 days after exemption

  2. Incidence of adverse events

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E, 4A and Part II: Within 14 days after each dose

  3. Incidence of adverse reactions/events

    Time frame: Part I Sections 1A, 2A, 2B: Within 30 minutes after exemption

  4. Incidence of adverse reactions/events

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E, 4A and Part II: Within 30 minutes after each dose

  5. Incidence of adverse reactions/events

    Time frame: Part I Sections 1A, 2A, 2B: Within 30 days after exemption

  6. Incidence of adverse reactions/events

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E, 4A and Part II: Within 30 days after each dose

  7. Incidence of Serious Adverse Event (SAE)

    Time frame: Part I Sections 1A, 2A, 2B: Within 180 days after exemption

  8. Incidence of Adverse Event of Special Interest (AESI)

    Time frame: Part I Sections 1A, 2A, 2B: Within 180 days after exemption

  9. Incidence of Serious Adverse Event (SAE)

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E, 4A and Part II: Within 180 days after the first dose to the booster dose

  10. Incidence of Adverse Event of Special Interest (AESI)

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E, 4A and Part II: Within 180 days after the first dose to the booster dose

  11. Abnormal laboratory test values

    Time frame: Part I Sections 1A, 2A, 2B: 4 days after exemption

  12. Seroconversion Rate of A, C, Y, W135 Group Meningococcal Antibody

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E, 4A: 30 days after primary vaccination, 30 days before and after booster vaccination

  13. Geometric Mean Titer (GMT) of A, C, Y, W135 Group Meningococcal Antibody

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E, 4A: 30 days after primary vaccination, 30 days before and after booster vaccination, at the age 3

  14. Positive Rate of A, C, Y, W135 Group Meningococcal Antibody

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E, 4A: 30 days after primary vaccination, 30 days before and after booster vaccination, at the age 3

  15. Geometric mean increase (GMI) of A, C, Y, W135 Group Meningococcal Antibody

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E, 4A: 30 days after primary vaccination, 30 days before and after booster vaccination, at the age 3

  16. Proportion of individuals with ≥1:128 titers for A, C, Y, W135 Group Meningococcal Antibody

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E, 4A: 30 days after primary vaccination, 30 days before and after booster vaccination, at the age 3

  17. Seroconversion rates of serum anti-Pertussis Toxoid (PT), Filamentous hemagglutmin (FHA), Pertactin (PRN), Diphtheria Toxoid (DT), Tetanus Toxoid (TT) antibody

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E: 30 days after primary vaccination, 30 days before and after booster vaccination, at the age 3

  18. Geometric Mean Concentration (GMC) of serum anti-PT, FHA, PRN, DT, TT antibody

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E: 30 days after primary vaccination, 30 days before and after booster vaccination, at the age 3

  19. Seropositivity rate of serum anti-PT, FHA, PRN, DT, TT antibody

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E: 30 days after primary vaccination, 30 days before and after booster vaccination, at the age 3

  20. GMI of serum anti-PT, FHA, PRN, DT, TT antibody

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E: 30 days after primary vaccination, 30 days before and after booster vaccination, at the age 3

  21. Percentage of serum anti-Hib-Polyribosyl Ribitol Phosphate (PRP) antibody concentrations ≥0.15 μg/ml

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E: 30 days after primary vaccination, 30 days before and after booster vaccination, at the age 3

  22. Percentage of serum anti-Hib-PRP antibody concentrations ≥1.0 μg/ml

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E: 30 days after primary vaccination, 30 days before and after booster vaccination, at the age 3

  23. GMC of serum anti-Hib-PRP antibodies

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E: 30 days after primary vaccination, 30 days before and after booster vaccination, at the age 3

  24. Seroconversion rate of serum anti-Hib-PRP antibodies

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E: 30 days after primary vaccination, 30 days before and after booster vaccination, at the age 3

  25. GMI of serum anti-Hib-PRP antibodies

    Time frame: Part I Sections 3A, 3B, 3C, 3D, 3E: 30 days after primary vaccination, 30 days before and after booster vaccination, at the age 3

07

Study locations

1 of 1 sites recruiting
  • Liangyuan District Center for Disease Control and Prevention, Shangqiu City
    Shangqiu, Henan, China
    Recruiting
    • Qiang Liu · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Feb 2029, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Oct 2, 2025
StartActual
Dec 19, 2025
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2029
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07203755
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Dec 19, 2025
Primary completion
Feb 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
Dec 31, 2025

Study contacts

Ying Wang
Contact
ying.wang@cansinotech.com
022-58213600-6051
Yanxia Wang
principal investigator · Henan Center for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion